News | March 10, 2008

Magnesium-Rich Foods Ward Off Stroke in Smokers

March 11, 2008 - Diets rich magnesium, found in whole grains and vegetables, could help reduce stroke risk in smokers, researchers Susanna Larsson and colleagues at the Karolinska Institute in Stockholm, Sweden, reported.

Their study of 26,000 male smokers in Finland found that those whose diets were high in magnesium had a significantly lower risk of one type of stroke.

While the mechanism is not clear, it may be that magnesium helps reduce high blood pressure, which can lead to stroke if untreated.

Researchers said the stroke finding was an offshoot of a study whose main purpose was to look at possible lung cancer therapies.

Cigarette smoking is strongly linked to stroke and it is the leading cause of heart disease and cancer.

The study of 26,556 Finnish men followed for more than 13 years found that those who consumed an average of 589 milligrams of magnesium each day in their diets had a 15 percent lower risk for cerebral infarction - a stroke that occurs when blood flow to the brain is blocked - than those who consumed less magnesium.

The effect was stronger for men younger than 60 and the study also found that calcium, potassium and sodium intake were not associated with risk for any type of stroke, the researchers reported in the Archives of Internal Medicine.

They said it remains to be seen if taking magnesium dietary supplements would produce the same result.

"In addition to lowering blood pressure, magnesium may influence cholesterol concentrations or the body's use of insulin to turn glucose into energy. Either of these mechanisms would affect the risk for cerebral infarction but not hemorrhage (the cause of other types of strokes)," Larsson's team wrote.

Besides whole grains, foods high in magnesium are black beans, broccoli, halibut, peanuts, oysters, rockfish and spinach.

Source: Reuters

For more information: www.reuters.com/article/healthNews

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init